Reactive Oxygen Species in Autoimmune Cells: Function, Differentiation, and Metabolism

Weiji Lin¹, Pan Shen¹, Yaqin Song², Ying Huang¹ and Shenghao Tu¹*¹

¹ Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ² Department of Emergency Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Accumulated reactive oxygen species (ROS) directly contribute to biomacromolecule damage and influence various inflammatory responses. Reactive oxygen species act as mediator between innate and adaptive immune cells, thereby influencing the antigen-presenting process that results in T cell activation. Evidence from patients with chronic granulomatous disease and mouse models support the function of ROS in preventing abnormal autoimmunity; for example, by supporting maintenance of macrophage efferocytosis and T helper 1/T helper 2 and T helper 17/regulatory T cell balance. The failure of many anti-oxidation treatments indicates that ROS cannot be considered entirely harmful. Indeed, enhancement of ROS may sometimes be required. In a mouse model of rheumatoid arthritis (RA), absence of NOX2-derived ROS led to higher prevalence and more severe symptoms. In patients with RA, naïve CD4⁺ T cells exhibit inhibited glycolysis and enhanced pentose phosphate pathway (PPP) activity, leading to ROS exhaustion. In this “reductive” state, CD4⁺ T cell immune homeostasis is disrupted, triggering joint destruction, together with oxidative stress in the synovium.

Keywords: reactive oxygen species, autoimmunity, macrophage, T cell, rheumatoid arthritis, metabolism

INTRODUCTION

Oxidative stress represents an imbalance between pro- and anti-oxidants, in favor of the former, and has generally been considered as potentially harmful, since it leads to phenomena including DNA damage, protein oxidation, and lipid peroxidation (1). Based on this dogma, items, such as antioxidant skin care products, natural foods, herbal medicine, and even vitamins have been in demand in recent decades. A typical example of the effects of oxidative stress is ROS-related cell aging. Strikingly, a recent study demonstrated that a modified oxidized form of cysteine residues in proteins is not elevated in old (80 weeks) compared with young (16 weeks) mice, providing strong evidence against the theory of oxidative aging, which involves accumulation of indiscriminate oxidation of biological macromolecules. This study found that protein oxidative state is tissue- and age-specific, and can influence various physiological networks. For example, reversible cysteine oxidation modification of hexokinase controls the flux of glycolysis and the PPP, and polymerization and dissociation of some protein complexes are also regulated by redox state. Researchers have proposed that oxidative modification site, rather than oxidative modification level, is the main target of anti-aging (2).
Numerous studies have demonstrated the role of oxidative stress in the pathogenesis of autoimmune disease, varying from biomacromolecule damage to pro-inflammatory responses (3); however, antioxidant supplements may be not beneficial for primary or secondary prevention (4, 5); indeed, beta carotene, vitamin A, and vitamin E supplements may increase mortality (6). In recent years, ROS has become widely regarded as a signaling molecule, involved in many immune cell relationships and functions (Figure 1). In this review, we discuss the importance of ROS in adaptive immune responses, and the damage to immune tolerance caused by excessive ROS elimination. Further, we provide a detailed review of the roles of redox regulation in the glycolytic/PPP equilibrium in CD4+ T cells, focusing on rheumatoid arthritis (RA) as a model autoimmune disease.

**ROS AND IMMUNE CELLS**

**ROS Production and Disease**

There are two main physiological sources of ROS: the NADPH oxidase complex, NOX2, and mitochondria. NOX2 is a multi-component enzyme system, composed of three cytoplasmic protein subunits (p47phox, encoded by NCF1; p67phox, encoded by NCF2; and p40phox, encoded by NCF4), two transmembrane protein subunits (p22phox, encoded by CYBA and gp91phox encoded by CYBB), and a small GTP-binding protein (Rac) (7, 8). In mitochondria, ROS production occurs when O2 receives an electron from the mitochondrial complex, which is a complex process influenced by the concentration of electron donors and O2, and the reactions rate constants between them (9). Chronic granulomatous disease (CGD) is an inherited disease, characterized by non-functional NOX2. Patients with CGD always suffer from recurrent life-threatening infections, due to deficient neutrophil- and macrophage-mediated innate immune responses. Interestingly, patients with CGD patients also have an increased risk of developing autoimmune diseases, resulting from their adaptive immune response disorder (8). In contrast, mitochondrial disease pathology is invariably considered to involve elevation of ROS (10); however, a study found that double mutants of alternative oxidases and severe myopathic skeletal muscle-specific COX15 gene mutation led to decreased ROS production, and consequent impairment of PAX7/MYOD-dependent muscle regeneration. This study indicated the benefits of mitochondrial ROS (mtROS) signaling and the potential hazards arising from ROS elimination (11).

**ROS in Antigen Presentation**

Mononuclear phagocytes and dendritic cell are the main professional antigen-presenting cells (APCs), in which exogenous antigens are proteolytically processed, then complexed, generally with MHC class II, or with MHC class I by a special process referred to as cross-presentation. NOX2-derived ROS in phagosomes can kill ingested pathogenic microorganisms and prevent excessive reduction of proteolysis and disulfide bond formation, by modulating the redox microenvironment, including the pH and oxidative modification of cysteine residues (12–14). In this way, the stability of effective epitopes of antigenic peptides and efficiency of their presentation are enhanced, so that APCs can better activate T cells. For example, activation of CD4+ T cell clones is regulated by NOX2-derived ROS through alteration of phagosome cysteine cathepsin activity, based on the immunodominant peptide epitope presented in the context of MHC Class II (14). In contrast, dendritic cells from p47phox-null mutant NOD mice (a spontaneous mouse model of autoimmune diabetes) and patients with CGD showed reduced ability to activate CD8+ T cells, due to antigen degradation and deficient antigenic peptide loading on MHC Class I (15). In addition, discovery of many oxidation autoantigens in APCs from individuals with autoimmune diseases indicated that ROS can change antigen structure directly, thus affecting T cell behavior (16, 17).

The other main source of ROS, MtROS may also influence the antigen presentation process in more complex ways. One study found that increased mtROS in aged murine dendritic cells (DCs) hampered the cross-presentation process, which could be restored by scavenging of ROS in vitro. This change is not influenced by phagocytosis function and pH (18); however, in plasmacytoid dendritic cells (pDCs), mtROS-dependent pH alkalization and antigen protection are key factors in induction of cross-presentation. This obvious difference may result from specialized toll-like receptor (TLR) activation and NOX2 independence of pDCs (19, 20). In pDCs, ROS also participates in responses to damage-associated molecular pattern (DAMP) molecules (such as mitochondrial DNA), and influences their capacity to stimulate pDCs (21). NOX2-derived ROS and mtROS may act synergistically, since one study found that, in macrophages that had already engulfed bacteria, mitochondria translocated and juxtaposed to the phagosome (22), and mtROS can be packaged by Parkin-based mitochondrial vesicles and transferred to bacteria-containing phagosomes (23).

Costimulatory molecules on the surface of APCs also influence the activation of adaptive immune cell. NOX2-derived ROS in dendritic cells endocytosing tumor cell-derived microparticles can upregulate the costimulatory molecules, CD80 and CD86, thereby activating CD8+ T cells. The underlying mechanism involves generation of the ROS-activated calcium channel, Mcoln2, in the lysosomal membrane, leading to Ca2+ release and activation of the transcription factor EB (TFEB), which can bind to the promoters of the genes encoding CD80 and CD86 (24, 25); however, in human primary monocytes infected by Epstein-Barr virus, TLR signaling activation increases ROS production. Further, ROS is an important contributor to marked up-regulation of the inhibitory costimulatory molecule, PD-L1, leading to immune escape (25); interestingly, the antioxidants, N-acetyl cysteine (NAC) and apigenin, can offset this change (26). In addition, alloantibody-FcγR I/FcγR III-dependent ROS production in macrophages is an important mediator of humoral immune damage during liver graft rejection (27). Opsonization of IgG on IFN-γ-activated macrophages led to diminished phagosomal processing of proteins in a PKC/Syk- NOX2-dependent manner, which occurs at the level of the individual phagosome (28). Altered IgG subtype distribution and the resulting increase in IFN-γ production are observed in both
Patients with CGD and a CGD mouse model (29), indicating a possible feedback loop involving IFN-γ, IgG, FcγRs, and NOX2.

**ROS and Macrophage Efferocytosis**

Macrophages are responsible for anti-pathogen immunity and ROS is a powerful weapon in this context. Reactive oxygen species promotes both M1 and M2 macrophage polarization (30), which appears to be contradictory, as the M1 phenotype is pro-inflammatory while M2 polarization is anti-inflammatory; however, the mechanism occurs in the context of mixed M1/M2 populations present under physiological conditions, defective innate immunity, and the tendency toward autoimmunity in patients with CGD. Normally, macrophages do not require antioxidants to protect themselves from ROS-related oxidative stress, because they possess defensive measures against ROS-mediated damage, such as the Mst-Nrf2 axis (31). In contrast, the addition of anti-oxidants may disturb macrophage-mediated autoimmunity, by altering macrophage polarization and homeostasis (30).

Efferocytosis is the process by which macrophages engulf and clear billions of apoptotic cells. Impaired efferocytosis plays a vital role in inflammation in CGD patients. Peritoneal, bone marrow-derived, and alveolar macrophages from NOX2-deficient mice and primary macrophages from CGD patients showed diminished efferocytosis of apoptotic Jurkat T cells and human neutrophils both in vivo and in vitro (32, 33). The mechanism involved has several aspects: “find me” signals in the prepare phase, “eat me” signals in the implementation phase and “digest me” in the rehabilitation phase.

“Find me” signals are some soluble substances released by apoptotic cells themselves, which recruit macrophages and reshape their scavenging potential. Among these signals, phagocytosis-related molecules such as ACP, GMP, creatine, spermidine, and glycerol 3-phosphate are reported as phagocyte gene expression modulators (34, 35). Interestingly, this characteristic of apoptotic cells seems to be changed in CGD mice. In zymosan A induced self-limited peritonitis CGD mice, researchers observed reduced macrophages/monocyte infiltration and delayed neutrophils clearance as well as...
diminished macrophage efferocytosis. The mechanism lays in defective respiratory burst in CGD neutrophils, thus failed to deplete local O$_2$ and produce enough ROS to maintain HIF-1α protein stability that is essential to upregulate macrophage efferocytosis enhancer erythropoietin-PPARγ signals (36).

As for “eat me” signals exposed on the surface of apoptotic cells, phosphatidylserine (PS) is the strongest (37). Apoptotic neutrophils in patients with CGD are prevented from PS externalization, as this process requires the participation of NOX2-derived ROS (33, 38, 39), which is verified by treatment of normal neutrophils with NOX2 inhibitor diphenyleneiodonium (33). And peroxidized PS species (PSox) are even stronger “eat-me” signals than PS alone (40). Further, PS exposure seems to modulate macrophage program such as classical and alternative activation in M1/M2 balance, above and beyond its effect on phagocytosis (32). M2, rather M1, macrophages are the protagonists of efferocytosis; and CGD patients and NOX2-deficient mice have macrophages with an M1 phenotype that tend to promote inflammation (32, 41, 42). Finally, the difference in efferocytosis ability between M1 and M2 macrophages is primarily attributable to the central role of interleukin 4 (IL-4) signaling through peroxisome-proliferator activated receptor γ (PPARγ). Ex vivo treatment of macrophages from patients with CGD and NOX2-deficient mice with IL-4 or IL-13 leads to re-establishment of normal efferocytosis, as do monocytes treated with the PPARγ agonist, pioglitazone (a drug for treatment of type 2 diabetes) (32, 43). PPARγ agonist treatment can not only reverse impaired efferocytosis in CGD monocytes, but also enhances mtROS production (43, 44). Interestingly, mtROS production can promote M2 macrophage polarization in the intestine (45).

Works go on in macrophage after ingesting apoptotic cells. In contrast to function of preventing excessive antigen reduction characterized in previous section, NOX2-derived ROS in the degradation of apoptotic cells seems to be a positive correlation: efferosomes maturation (acquisition of LC3 and LAMP-1), enhanced acidic environment mediated by V-ATPases, competent proteolytic activity, and these are obviously delayed in macrophage of CGD patients. The key element of this difference lies on the nature of phagosomal protein cargo. Apoptotic neutrophil cargo contributes to activation of macrophage NOX2 in a CD11b-TLR2/TLR4-myeloid differentiation primary response 88 (MyD88)-dependent manner and the subsequent ROS production, which is significantly delayed in macrophages from NOX2-deficient mice (46). While IgG-opsonized antigen cargo activates NOX2 dependent on FcγR-PKC/Syk pathway rather than V-ATPase (13, 28, 46).

NOX2 deficiency has been identified as associated factor in autoimmune disease. For example, Ncf1 polymorphism is a stronger genetic factor of systemic lupus erythematosus (SLE) (47). It is well-known that autoantigen triggered autoantibody plays a vital role in pathology of SLE, and this process is dramatically enhanced in experimental lupus in NOX2 deficient mice (48, 49). Failure in timely clearance of apoptotic cells that is founded in NOX2 deficient lupus mice contributes to accumulation of secondary necrotic cells leading to increased secretion of inflammatory cytokines and chemokines (50).

**The Effects of ROS on T Helper 1/T Helper 2 and T Helper 17/Regulatory T Cell Balance**

It is widely accepted that ROS is essential in adaptive immunity. T cell receptor (TCR) activation is accompanied by production of large amounts of ROS over a few minutes (51), which is associated with mTOR/AMPK axis-mediated metabolic reprogramming (52, 53). Reactive oxygen species is a critical link in the signaling events mediating T cell activation, proliferation, and differentiation (54, 55); however, number of studies have contradicted these findings (56). Here, we review understanding of the function of ROS in T helper 1 (Th1)/T helper 2 (Th2) cell, and T helper 17 (Th17) cell/regulatory T cell (Treg) balance, the importance of which in autoimmune is universally acknowledged.

Th1/Th2 were the first CD4$^+$ T helper cell subsets determined to contribute to autoimmune diseases (57). Characterized by IFN-γ and IL-2, Th1 cells mainly function in cellular immunity, while Th2 cells are focused on humoral immunity. The Th1/Th2 equilibrium manifests in both directions during autoimmune disease; for example, the Th1 predominance in RA (58) and Th2 advantage in SLE (39). Further the Th17/Treg equilibrium has a major role in inflammatory and autoimmune diseases (60). Interconnected developmental pathways facilitate the plasticity between Th17 and Treg phenotypes in various inflammatory (61) and oxidative (56) microenvironments.

Evidence from patients with CGD and NOX2-deficient mice includes experimental data on the “third signal” function of ROS in Th1/Th2 and Th17/Treg balance (Table 1). In NOX2-deficient mice, the T cell phenotype is skewed toward the Th1 and Th17 lineages (62, 63, 67), while macrophage-restricted restoration of ROS production improved resistance to collagen-induced arthritis in NOX2-deficient mice (68). This effect may depend on Treg induction by macrophage-derived ROS, and was confirmed in experiments using macrophages from patients with CGD (64). Further, compared with wild-type mice, Tregs from NOX2-deficient mice exert much weaker inhibition of CD4$^+$ effector T cells (65), and antioxidant NAC or NOX inhibitors also induce changes in the Th1/Th2 and Th17/Treg balance (Table 2). However, it is noteworthy that NOX2 deficiency in combination with transgenic mice shows different change of T cell subsets. For example, NOX2 deficiency in OT-II mice (a transgenic mouse model with antigen-specificity for chicken ovalbumin 323-339 in CD4$^+$ T cell) lead to both decreased Th1 and Th17 lineages in contrast with NOX2-deficient mice (66). Further, NOX2 deficiency in NOD mice serves as protector reflected in significant reduction and delay in autoimmune diabetes development (67, 70, 71). And macrophage, CD4$^+$ T cell, CD8$^+$ T cell are involved in the protection (Table 3). Weakened Th1 lineage proficiency resulted from absence of Th1 transcription factors (T-bet, STAT4, and STAT1α) and Th17 prominence by STAT3 activation are observed in NOX2-deficient NOD mice (67). Followed research revealed that the protection afforded by NOX2 deficiency is rely on ROS lack in macrophages and DCs leading to reduced CD4$^+$ T-cell autoreactivity [one possible mechanism is reduced MHC-II
complex by macrophage (72)] and CD8⁺ T cell effector function [one possible mechanism is defective cross presentation by DC (15)], rather than isletβ-cell and neutrophils (70). Surprisingly, NOX2 deficiency in NOD.BDC-2.5 mice (a TCR transgenic mice whose TCR specifically recognizes islet antigen) that was meant to prevent from autoimmune diabetes has instead resulted in spontaneous type 1 diabetes. In followed adoptive transfer experiment, CD4⁺ T cells of NOX2-deficient NOD.BDC-2.5 mice were more diabetogenic upon adoptive transfer into NOD due to less suppressive Tregs (73). These studies implied the complication of ROS in immune cell response to heterogeneous microenvironment.

A key factor influencing Th1/Th2 differentiation from Th0 cells is the cytokine microenvironment, where APC represent a cytokine source. If glutathione (GSH; a major cellular antioxidant) is depleted in APCs over a short time period, production of Th1-associated cytokines will be inhibited and Th2-associated cytokine generation favored (74). Similarly, low doses of H2O₂ can prevent activated Th1 clones from producing INF-γ and potentiate IL-4 secretion by activated Th2 clones (75). T cell activation-triggered IL-2 and IL-4 expression is partly dependent on ROS generation and follows oxidative signaling via mitochondrial respiration chain complex I. Inhibition of complex I function will decrease mtROS generation, thus blocking activation-induced secretion of IL-4 in CD4⁺ T cells from patients with atopic dermatitis, a disease characterized by elevated IL-4 and IgE. Prolonged ciprofloxacin treatment has the same effect on CD4⁺ T cells as the complex I inhibitor, rotenone, which may explain the immune regulation function of ciprofloxacin (76). The transcription factor, Bach2, plays a vital role in shaping the balance between CD4⁺ T cell subsets (77). TCR signaling induced by ROS specifically limits the degradation of the SUMO-specific protease, SENP3, leading to its rapid accumulation in Tregs. SENP3 promotes Bach2 deSUMOylation and prevents its nuclear export, which inhibits the expression of IFN-γ, IL-17, and other effector cytokines, and maintains Treg-specific gene signatures (78). Reactive oxygen species promote PAC1/DUSP2 expression by activating the

### Table 1

| Cell type | NOX2 mutation | Th1 change | Th2 change | Th17 change | Treg change | Other |
|-----------|----------------|------------|------------|-------------|-------------|-------|
| CD4⁺ T cell of C57BL/6 (62) | gp91phox⁺ | IL-2 ↑ | IL-4 ↓ IL-5 ↓ | NA | NA | TNF ↑ |
| Total splenocytes of C57BL/6 (63) | gp91phox⁺ | IFN-γ ↑ | NA | IL-17 ↑ | NA | NA |
| Naïve CD4⁺ T cells of C57BL/6 (63) | gp91phox⁺ | IFN-γ ↑ T-bet ↑ | IL-4 ↓ IL-4 Fa ↓ IL-5 ↓ GATA-3 ↓ | IL-17 ↑ | NA | STAT5 Phosphorylation ↓ |
| PBMC from CGD patients (64) | p47phox⁺ | NA | NA | NA | No change of CD4⁺CD25⁺ Fox3⁺ cells | NA |
| Total spleen cell from C57BL/6 (65) | p47phox⁺ | NA | NA | NA | No change of CD4⁺ Fox3⁺ cells | NA |
| Spleen CD4 T cells of OT-II mouse (66) | p47phox⁺ | IL-2 ↓ IFN-γ↓ CD4⁺ T-bet⁺ cell↓ | IL-17A↓ | NA | IL-10↓ | TNF-a↓ TGF-β↓ IL-5↓ IL-12p70↓ |

Frequencies of Th1, Th2, Th17, Treg cells, or levels of related cytokines are compared between immune cells from NOX2 mutation mice/CGD patients and wild type mice/healthy people. ↑: levels of cytokines or frequencies of cells are higher than wild type mice/healthy people. ↓: levels of cytokines or frequencies of cells are lower than wild type mice/healthy people.

### Table 2

| Cell type | Treatment | Th1 change | Th2 change | Th17 change | Treg change | Other |
|-----------|-----------|------------|------------|-------------|-------------|-------|
| CD4⁺ T cell from BALB/c mice (63) | 10 mM NAC (ROS scavenger) | IFN-γ ↑ | IL-4 ↓ IL-5 ↓ | NA | NA | STAT5Phosphorylation ↓ |
| Human CD4⁺CD25⁻ T cells (64) | Primed with macrophage from p47phox⁺-CGD patients | IFN-γ ↑ | NA | IL-17 ↑ | CD4⁺CD25⁺Fox3⁺ cell ↓ | NA |
| CD4⁺ CD45RO⁻ T-cells under Th1- and Th17-skewing conditions (65) | Tempol (ROS scavenger) | IFN-γ⁺ cells ↑ | NA | IL-17+ cells ↑ | NA | NA |

Thayer et al. (70) immune cells whether receiving ROS clearing treatment, or primed with macrophage from CGD patients and healthy people. ↑: levels of cytokines or frequencies of cells are higher than control group. ↓: levels of cytokines or frequencies of cells are lower than control group.
TGF-β is a cytokine with broad regulatory functions in T cell development and differentiation. The complexity of TGF-β-related signaling is partly reflected in its contradictory functions and mechanisms in Th17/Treg differentiation. TGF-β is normally synthesized as a precursor, whose C-terminal portion is referred to as latency-associated peptide (LAP). LAP is cleaved by Furin, to generate latent TGF-β, which can occur both intracellularly and extracellularly (82). Latent TGF-β can be activated by various molecules, including integrin αvβ8 and ROS in T cells (83, 84). Human CD4+ CD25− naïve T cells can be induced to express Foxp3 by stimulation with anti-TCR and anti-CD28 antibodies plus ROS (85). This effect relies on production of latent TGF-β by TCR and CD28 engagement, as well as subsequent activation of latent TGF-β by ROS on TCR stimulation (84). Promotion of Th17 generation by high glucose and Treg generation by D-mannose are dependent on addition of exogenous latent LAP-TGF-β, rather than active TGF-β, indicating that activation related signals contribute to this effect, but not active TGF-β itself (86, 87) (Figure 2). Why active TGF-β does not function in this context and how the “activation-related signals” promote TGF-β signal transduction remain unclear; we speculate that intercellular communication, controlled by receptor-mediated TGF-β activation, may be a contributing factor, while “activation-related signals” may trigger some change that influences TGF-β signal transduction. Reactive oxygen species are key intermediary molecules for activation of latent TGF-β, and NAC abolishes the induction of Th17 cells and Tregs (86, 87). Reactive oxygen species not only acts as an upstream molecule to activate latent TGF-β, but also participates in TGF-β-Smad signaling. Missahen (Msn)/NIK-related kinase 1 (MINK1) is a serine-threonine kinase that can induce Th17 differentiation by directly phosphorylating the T324 site at the α1 helix region of the Smad2 protein (88). Reactive oxygen species are involved in activation of MINK1 (89), and NAC treatment profoundly reduced MINK1 activity and increased the frequency of IL-17A+ cells, which did not occur in MINK1-deficient T cells. The processes described above are shown in Figure 2. Further, in Th17 cells differentiated from MOG35–55-immunized CD4+ T cells, NAC treatment resulted in more severe experimental autoimmune encephalomyelitis (EAE) disease after transfer into Rag1−/− mice (88), while knockout of GSH in T cells led to EAE resistance in mice. IsoalloLCA is a bile acid metabolite, which can enhance mROS production in CD4+ T cells. Elevated mROS increased H3K27 acetylation at the Foxp3 promoter region in a TGF-β-Smad3 signal dependent manner, thereby promoting Treg differentiation (90). Moreover, ROS also contributes to suppression of CD4+ effector T cells mediated by Tregs, which is partly dependent on TGF-β and can be blocked by thiol-containing antioxidants (65).

Abnormal redox related Th subsets change has been identified in autoimmune diseases, such as RA. Naïve CD4+ T cells from RA patients possess a distinct carbohydrate metabolic signature,
Lin et al. ROS in Autoimmune Cell

FIGURE 2 | ROS participate in Th17/Treg balance. ROS are involved in TGF-β mediated Th17/Treg balance. Latent TGF-β formed after LAP in the TGF-β precursor was cut by Furin, and then ROS activated TGF-β from its latent form. NOX2 or mitochondrion derived ROS activated MINK1 that inhibits the phosphorylation of Smad2 in T324 residue, so that expression of Th17-associated genes is blocked, and ROS scavenger NAC will reverse this function. ROS also participate in expression of Treg-associated genes.

which is manifested as an excessive shunt of glucose into the PPP, resulting in high levels of reduction mediated by GSH and NADPH, and exhaustion of ROS (69, 91, 92). Low levels of ROS lead to ataxia telangiectasia mutated (ATM) deficiency, causing rapid T cell proliferation and differentiation toward Th1 and Th17 lineages (69, 91); however, in a study of inflammasomes in RA, naïve CD4+ T cells from RA patients produced more ROS compared with those from healthy controls (93); this contradictory result may be attributable to measurement being conducted as early as 8 h after anti-CD3/CD28 stimulation, which is much earlier than the 3–6 day time points used in two other studies (69, 92). In those reports, treatment of CD4+ T cells from RA patients with the pro-oxidant, plumbagin, reduced the frequencies of Th1 and Th17 cells, as well as decreasing production of the inflammatory cytokines, TNF-α and IL-6. The antioxidant, NAC, completely reversed the regulatory effects of plumbagin (94). These studies demonstrate the potential pro-inflammatory function of ROS exhaustion in RA CD4+ T cells, and anti-inflammatory benefits of supplementation with oxidants.

Based on the evidence reviewed above, it remains unclear how strong the effect of ROS is in autoimmunity-related Th1/Th2 and Th17/Treg balance. Regarding patients with CGD, it is difficult to determine a clear role of CD4+ T cells in CGD-related autoimmunity risk. For example, one study reported that only gp91phox-deficient CGD is associated with diminished Tregs (95); however, a review demonstrated that oxidative stress leads to T-cell dysfunction in SLE by altering Th cell lineages and gene transcription (96).

ROS and Inflammatory Metabolism: Kyn-IDO1

Indoleamine 2,3-dioxygenase (IDO) has maintained a central role in tryptophan metabolism over hundreds of millions of years of evolution (97, 98). It is well-established that IDO has suppression and feedback roles in immune regulation (99), and clinical trials of IDO inhibitors for treatment of cancers were very successful. The normal dioxygenase activity of IDO is post-translationally activated by biological reduction of Fe3+ to Fe2+ in heme. Of these reducing agents, ROS, and particularly superoxide anion (O2−), are most widely studied in mice and rabbit (100, 101). Specifically, hyperbaric oxygen can increase kynurenine concentration in rat brains by 60% compared with air (102). In murine atopic dermatitis and psoriasis lesions, hyperbaric oxygen therapy can elevate ROS levels to attenuate disease, which may be mediated by enhanced IDO expression and Treg function (103, 104). Precisely because of the immunosuppressive effect of IDO and its ROS dependency,
defective IDO activation and tryptophan metabolism were once considered to be important factors contributing to hyper-inflammatory responses in murine CGD (101, 105). Interestingly, long-term evolution appears to have freed human IDO activity from ROS restriction. The IDO metabolic activity of leukocytes and monocyte-derived dendritic cells is fully maintained and intact in human patients with CGD (106–108), indicating that ROS is not indispensable for human IDO activity. Cytochrome b5, rather than ROS, has a major role in IDO reduction in human cells (100, 109); however, it is not clear whether the entire tryptophan metabolism process is independent of ROS in humans. LPS-induced ROS promotes DC maturation mediated by IDO and NF-kB activation, leading to expansion of CD4+ CD25high Tregs (110). A tryptophan catabolite of IDO, L-kynurenine (Kyn), can induce apoptosis of NK cells in a ROS-dependent manner. This pro-apoptotic effect can be entirely prevented by the antioxidant, NAC (111). In turn, Kyn also can elevate ROS levels in activated T cells and promote their proliferation, which relies on inhibition of sepiapterin reductase, the terminal enzyme in the de novo tetrahydrobiopterin synthesis pathway (112). Further, IDO1 can even produce single molecular oxygen in the presence of hydrogen peroxide. The generated \( ^1O_2 \) oxidizes L-tryptophan to a tricyclic hydroperoxide, thus regulating vascular tone and blood pressure under inflammatory conditions (112).

**ROS AND RHEUMATOID ARTHRITIS**

Due to the physiological function of ROS, high levels of reducing equivalents and excessive ROS scavenging may lead to damage of the opposite type to oxidative stress, sometimes referred to as reductive (113) or antioxidative (114) stress.

Redox regulation treatments should be disease-specific as the different redox characteristics among diseases. For example, unlike the central role of oxidative stress in lupus pathogenesis, CD4+ T cells of RA patients experienced reductive stress (115). In addition, variations in redox state exist among types of lesions and cells in RA. In the next section, we discuss the metabolic origin of these variations and their influences on pathology.

**ROS in RA: Every Coin Has Two Sides**

RA pathogenesis is not well-understood, but can be summarized by loss of peripheral immune tolerance to autoantigens, followed by excessive activation of T and B cells, leading to increased levels of cytokines and autoantibodies (rheumatoid factor, anti-cyclic citrullinated peptide antibodies, etc.). The homeostasis between pro- and anti-inflammatory states is destroyed, eventually leading to damage of multiple joints and other organs throughout the body.

Numerous studies have confirmed the vital role of ROS-related oxidative stress in joint pathology, including in angiogenesis, synovial proliferation, and inflammatory infiltration (116, 117). Further, functional genetic analysis showed that the rs201802880 polymorphism in the NCF1 coding region is associated with genetic susceptibility to RA (47). Patients with CGD also have increased susceptibility to RA (47, 118). Moreover, a study of NOX2-deficient mice demonstrated that the absence of ROS prevents resistance to autoimmune arthritis. A collagen-induced arthritis model generated by Ncf1 mutation in mice has more severe symptoms, higher anti-CII IgG levels, and stronger Th1 responses than wild-type mice, which can be reversed by restoration of functional Ncf1 solely in macrophages. Interestingly, this research also found that T cells from Ncf1-mutated mice responded more vigorously to APCs (68). Mice with mutated mouse collagen (MMC) have higher resistance to arthritis mediated by a mutated immunodominant epitope in collagen type II that binds to the MHC class II molecule. When these MMC mice are bred with NOX2-deficient mice, their immune tolerance to arthritis disappears, and they exhibit enhanced autoimmune T cell responses and higher anti-CII IgG levels (119).

Poly-N-isopropylacrylamide (PNiPAAm)-based polymers are new synthetic substances that can serve as adjuvants in inducing experimental arthritis. Mixture of these new “adjuvants” with natural CII triggers more severe arthritis and stronger autoantibody responses in Ncf1-mutated mice, in which macrophage ROS also plays a central role (120). DC function is also influenced by redox state. *Mycobacterium tuberculosis*-activated DC with ROS exhaustion (through incubation with SOD and catalase, or derived from NOX2-deficient mice) produced more IL-1β, TNF-α, TGF-β, and IL-6. NOX2 mutation breaks the resistance to arthritis of wild-type C57BL/6 mice, and this is CII specific, as Freund's complete adjuvant alone cannot induce arthritis. In addition, when DC from NOX2-deficient mice serve as APC, T cells produce more IL-17 after activation by toxic shock syndrome toxin-1 (TSST-1) (121); however, research into SKG mice (a spontaneous arthritis animal model caused by ZAP70 mutation) indicates that Ncf1 mutation-related ROS deficiency does not exhibit further alteration of T-cell activation or differentiation profile because of ZAP70 mutation, while transgenic restoration of functional Ncf1 in macrophages modified the arthritis in Ncf1-mutated SKG mice to the state observed in ROS-sufficient SKG mice. This research indicates that innate, but not adaptive, inflammation contributes to more severe arthritis related to ROS deficiency (122). Therapeutic strategy that increasing NOX2-derived ROS has been tested, in which phytol, an oxidative burst-inducing substance, ameliorated pristane induced rat arthritis in T cell and IFN-β-dependent pathway (123, 124). Other free radicals, namely reactive nitrogen species, also contribute to arthritis pathogenesis in Ncf1-mutated mice, and may counteract the effects of ROS. Treatment with the NOS inhibitor, L-NAME, in the priming, rather than the effector, phase prevents Ncf1-mutated mice from developing CII-induced arthritis (125).

**The Reductive State in RA Naïve CD4+ T Cells**

Subsets of CD4+ T cells, including Th17 cells and Tregs, are recognized as important targets for the treatment of autoimmune disease; however, few studies have concentrated on the role of naïve CD4+ T cells. After recognizing the MHC complex, naïve CD4+ T cells initiate rapid clonal expansion, with a consequent explosive increase in energy and biosynthesis.
demands. The energy demands are dependent on transformation from oxidative phosphorylation to glycolysis, referred to as metabolic reprogramming (52). This may appear to be a retrogression, where an efficient method of ATP generation is abandoned in favor of a wasteful method; however, glycolysis actually is the more logical choice for cells undergoing rapid proliferation. Oxidative phosphorylation has a much higher proteome costs than glycolysis, because of the prerequisite complicated mitochondrial infrastructure, that requires huge energy expenditure (126). The enhanced PPP and glutamine decomposition meet the NADPH and biosynthetic precursor needs during T cell growth and proliferation (127), and both participate in GSH generation. The balance of energy generation and biosynthesis is also very important. In contrast, deficiency of any of these processes will destroy the basic support for normal physiological activities after T cell activation. In contrast, excessive glycolysis is associated with pro-inflammatory T cell subsets (128) and excessive biosynthesis indicates a worse outcome (i.e., a tumor). In normal naïve CD4+ T cells, glycolysis activation occurs in response to upregulation of the glucose transporter, GLUT, which increases glucose uptake (129), and activities of several rate-limiting enzymes, including 6-phosphofructo-1-kinase (PFK-1) (130). PFK-1 activity is mainly dependent on allosteric activation by fructose-2,6-bisphosphate (F2,6BP), and production of F2,6P2 is primarily controlled by four fructose-2,6-bisphosphatase (PFKFB) isoenzymes (131), among which PFKFB3 is the strongest. During the activation of CD3+ T cells, PFKFB3 expression is increased in response to engagement of the TCR and the co-stimulatory receptor, CD28 (132). Two studies found that, compared with those from healthy people, naïve CD4+ T cells from patients with RA failed to upregulate PFKFB3 expression during the activation process, leading to reduced glycolytic flux and diminished ATP generation. As a rate-limiting enzyme of the PPP, glucose-6-phosphate dehydrogenase (G6PD) initiates the PPP by dehydrogenation of glucose 6-phosphate. Unlike PFKFB3, these naïve CD4+ T cells successfully upregulated G6PD expression, which controls the fate of residual glucose, namely, influx to the PPP. Hence, there is an imbalance of energy generation and biosynthesis in naïve CD4+ T cells from patients with RA, resulting in accumulation of GSH and NADPH, reduced ATP generation, and ROS exhaustion (Figure 2) (60, 79).

Altered Metabolism Influences T Cell Differentiation and Proliferation
Glutaminolysis is a basic and widespread metabolic process that links oxidative phosphorylation (OXPHOS), biosynthesis, and redox regulation. The main branch point hinges on glutamate, the first product of glutamine decomposition, which can serve as material for de novo synthesis of GSH to regulate oxidation, or transform into α-KG and enter the TCA cycle to generate ATP, mtROS, and biosynthetic precursors. Hence, the different destinies of glutamate generate counteracting metabolites (GSH and ROS), facilitating precise coordination of metabolic flux by altering enzyme activity (133). Activation of primary T cells requires rapid glutamine uptake mediated by the amino acid transporter, ASCT2 (127). Glutaminolysis inhibition of CD4+ T cells has an anti-inflammatory function in autoimmunity, promotes high levels of Foxp3 expression (134) and decreases Th17 differentiation in SLE and EAE (135, 136). In RA, fibroblast-like synoviocytes (FLS) express increased levels of glutaminase 1, and inhibition of glutaminase 1 reduces RA-FLS proliferation (137); however, there has been no study of the glutaminolysis phenotype of RA naïve CD4+ T cells. Given the dysregulated redox state in RA T cells, whether or not glutaminolysis contributes to this phenomenon warrants discussion and study.

Other than sharing the same substrates, connections between PPP and glycolysis also include their interactions in metabolic signaling. Although excessive PPP and accumulated GSH lead to reductive stress in RA primary CD4+ T cells, T cells lacking GSH also appear to be incapable of initiating metabolic reprogramming, because of impaired Myc expression, NFAT activation, and mTOR activation. Higher ROS levels appear to be the protagonist, as ROS scavengers reverse the influence of lack of GSH (138). Briefly, both high levels of ROS and exhaustion of ROS harm normal transfer into glycolysis during metabolic reprogramming following T cell activation; recalling the old Chinese idiom, “Beyond is as wrong as falling short.”

Similar with the higher risk of fetal deformity occurring during the first 3 months of pregnancy, naïve CD4+ T cell may represent a stage at which pathogenic factors can readily influence T cells, with pathological changes at this stage having profound and lasting influences. Reactive oxygen species exhaustion disturbs normal DNA repair capabilities in naïve CD4+ T cells from patients with RA, and ATM insufficiency is a key factor influencing this phenomenon (69, 139). The resulting accumulation of DNA damage, ATP deficiency because of reduced glycolysis, and impaired autophagy induction (92) mean that naïve CD4+ T cells are more sensitive to apoptosis, leading to an abnormal loss of T cells. Since patients generally present with RA in middle-age, it is T cell auto proliferation, rather than newborn T cells, that maintain homeostasis of the T cell compartment. Remaining T cells are confronted with replicative stress, under the influence of lymphopenia, excessive biosynthesis, and pro-inflammatory cytokines. Consequently, the T cell immune aging process begins (140, 141). In addition, this imbalance supports pro-inflammatory functions, such as Th17 lineage expansion and enhanced synovial invasiveness (69, 142).

Division of Glycolysis Between Naïve CD4+ T Cell and Synovium in RA: Hypoxia, Lactic Acid, and ROS
Hypoxia has been identified as a constant feature of RA synovial tissue, which occurs in the pre-arthritic phase because of increased cell proliferation, capillary network collapse, and maintenance of the inflammatory phase, due to invasive synovial proliferation, dysregulated architecture of the microvasculature, and pro-inflammatory signals, such as HIF-1α and JAK–STAT signaling (143). In energy metabolism, hypoxia is always accompanied by aerobic glycolysis and mitochondrial dysfunction, leading to accumulation of lactic acid and ROS.
and glycolysis metabolites, such as macrophage polarization, tumor immunity, and antiviral responses (9). Indeed, accumulated lactic acid supports pro-inflammatory T cells to remain at the double-positive stage and produce more IL-17 (144, 145), while ROS causes oxidation with broad impacts (116, 117); however, as discussed above, in CD4+ T cells at the preliminary stages of RA, glycolysis is decreased and ROS is exhausted, resulting in a reductive metabolic microenvironment (low pyruvate and high NADPH) and triggering aberrant lipogenesis. This induces up-regulation of the podosome scaffolding protein, TXS5, and formation of cell membrane structures beneficial to T cell synovial invasion (142). Interestingly, this division of glycolysis between RA T cells and the synovium may combine to induce joint destruction: pro-inflammatory T cells invade synovial tissue quickly and easily, while departure is more difficult (Figure 3). In addition, lactate, which was once considered a metabolic waste product, is now thought to act as a homeostatic regulatory substance capable of counteracting the inflammatory responses caused by HIF1α and glycolysis metabolites, such as macrophage polarization, tumor immunity, and antiviral responses (146), and the newly discovered histone lysine lactate modification, lactylation, may be an important mechanism underlying these processes (147). Therefore, the decreased lactate levels in RA naïve CD4+ T cells, due to deficient glycolysis, may also contribute to the immune pathology of RA.

PROGRESSIVE OPINION IN REDOX MODULATION

Studies indicate that oxidatively modified lipids, proteins, and nucleic acids, may be typical of atherosclerosis. Oxidation of low-density lipoprotein has been clearly identified as an important initial event for the onset of atherosclerosis (148). Further, regarding oxidative stress in immune-related disease, oxidatively modified autoantigens are a major topic of interest, because of their induction of loss of immune tolerance. Nevertheless, cardiovascular patients do not benefit from antioxidant supplements (5), and their effects in autoimmune diseases, such as RA, are highly contentious (149–151).

Several points may explain the failure of “one-size-fits-all” antioxidant supplements in human studies. First, the reactivity of antioxidants is dependent on the oxidants they encounter, and rate constants are highest in specific pairs: α-tocopherol and peroxy radical, glutathione and peroxynitrous acid, ascorbic acid and carbonate anion radical, glutathione and hypochlorous acid, and β-carotene paired with singlet oxygen (152). In view of different types of oxidative modification of biological macromolecules in various degenerative and aging related diseases, as well as selectively or indiscriminately produced oxidation products, application of bulk antioxidants are expected to be more precise and targeted. Second, bioavailability in target organs is a key factor. Take ischemic stroke for example, edaravone works by eliminating free radicals and suppressing oxidative stress. However, low bioavailability and inefficient penetration across the blood-brain barrier limits the curative. Treatments based on drug nano-systems loading with edaravone possess better scavenging efficiency of free radicals (153, 154). Third, different roles of antioxidants between target organ and the others may be an important reason for side effects. In view of ROS as the key beneficial messenger in the barrier ecosystem, oral administration of antioxidants which is the main application way by people, may starts its disturbance on the body upon first barrier—gastrointestinal tract (155).

Inspired by these findings in exogenous antioxidants, new strategies may combat oxidative stress shifts by promoting innate redox modulation systems; For example, by increasing the level of endogenous NADPH (156). Another meaningful progress is the use of the SOD mimics. Superoxide dismutase 2 (MnSOD) is a part of innate redox modulation systems, which plays an important role in regulating the ROS level in mitochondria. Based on therapeutic potential of MnSOD in human diseases, SOD mimics have been developed and are currently in several clinical trials (157). Interestingly, due to the redox potential falling in between the potentials for the oxidation and reduction of O•−, these MnSOD mimics are capable of role transformation from reductants to oxidants decided by chemical properties of the reaction and the cellular environment (157). Except for drug therapy, there are some special treatments promoting redox balance and deserve attention. A recent study found static magnetic and electric fields rapidly ameliorate insulin resistance and glucose intolerance in type 2 diabetes dependent on mitROS induction, and SOD2 application fully abolishes these positive effects (158). Further, exercise especially acute exercise is widely believed a process producing large numbers of ROS which causes skeletal muscle damage, fatigue and impair recovery. As a result, antioxidants supplement has become common practice. However, several reviews have well-characterized that increase of free radicals explain the health promotion effect of exercise, and antioxidants supplement reduce the positive effects of exercise (159–161). These discoveries imply the potential bidirectional therapy, which fits the point we mentioned in this review: enhancement of ROS may sometimes be required in diseases.

CONCLUSION

Unlike their past reputation as harmful factors, a focus on ROS as important signaling molecule has developed in recent years. A typical example of this change in research direction is illustrated by the fact that tissue-specific redox modification of proteins has replaced biomacromolecule damage as the main agent involved in the process of aging. Failures of clinical trials into antioxidant supplements led scientists to deeply consider the problems of whether and how antioxidant strategies should be implemented.

This review has discussed the important roles of ROS in various autoimmune functions. For example, ROS influences interactions between innate and adaptive immunity by controlling the antigen presentation and apoptotic cell clearance. Evidence from NOX2-deficient mice and patients with CGD support the functions of ROS in regulating Th1/Th2 and Th17/Treg balance. Immunometabolism is an important process to which ROS contributes. Tryptophan metabolism
deficiency contributes to the stronger, harmful inflammatory response in CGD mice. Regarding autoimmune diseases, such as RA, alterations in glucose metabolism-related redox imbalance have broad impacts. Due to glucose shunting into the PPP from glycolysis, naïve CD4+ T cells from RA patients are a good cellular level model system to explore T cell immune responses in a naturally ROS deficient environment. This special change in metabolism and redox balance leads to DNA repair deficiency, susceptibility to apoptosis, and differentiation into inflammatory subsets of RA naïve CD4+ T cells. In addition, although the metabolism and redox state in RA synovial tissue are completely contrary to that of naïve CD4+T cells, we speculate that they act in combination to mediate joint destruction; however, the origin of this specific type of metabolic reprogramming remains unclear, and whether ROS contributes to triggering this process also awaits further investigation.

Overall, ROS clearance may be beneficial in specific situations, but harmful in others. Under no circumstances should we regard antioxidant supplements as completely...
REFERENCES

1. Sies H, Oxidative stress: from basic research to clinical application. Am J Med (1991) 91:31s–8s. doi: 10.1001/0002-9343(91)90281-2
2. Xiao H, Jedrychowski MP, Schwepp DK, Hurtlin EL, Yu Q, Heppner DE, et al. A quantitative tissue-specific landscape of protein redox regulation during aging. Cell (2020) 180:968–83.e24. doi: 10.1016/j.cell.2020.02.012
3. Franchina DG, Dostert C, Brenner D. Reactive oxygen species: involvement in T cell signaling and metabolism. Trends Immunol. (2018) 39:489–502. doi: 10.1016/j.it.2018.01.005
4. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. (2012) 3:CD007176. doi: 10.1002/14651858.CD007176.pub2
5. Myung SK, Ju W, Cho B, Oh SW, Park SM, Koo BK, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ (Clin Res Ed.). (2013) 346:f10. doi: 10.1136/bmj.f10
6. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. (2007) 297:842–57. doi: 10.1001/jama.297.8.842
7. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. (2007) 87:245–313. doi: 10.1152/physrev.00044.2005
8. O’Neill S, Brault J, Stasia MJ, Knaus UG. Genetic disorders coupled to ROS deficiency. Redox Biol. (2015) 6:135–56. doi: 10.1016/j.redox.2015.07.009
9. Murphy MP, How mitochondria produce reactive oxygen species. Biochem J. (2009) 417:1–13. doi: 10.1042/BJ20081386
10. Lin DS, Huang YW, Ho CS, Hung PL, Hsu MH, Wang TJ, et al. Oxidative insults and mitochondrial DNA mutation promote enhanced autophagy and mitophagy compromising cell viability in pluripotent cell model of mitochondrial disease. Cells. (2019) 8:65. doi: 10.3390/cells8010065
11. Dogan SA, Cerutti R, Benincà C, Brea-Calvo G, Jacobs HT, Zeviani M, et al. Perturbed redox signaling exacerbates a mitochondrial myopathy. Cell Metab. (2018) 28:764–5.e5. doi: 10.1016/j.cmet.2018.07.012
12. Savina A, Jancic C, Hugues S, Guernonprez P, Vargaz P, Moura IC, et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell. (2006) 126:205–18. doi: 10.1016/j.cell.2006.05.035
13. Rybicka JM, Balce DR, Khan MF, Krohn RM, Yates RM. NADPH oxidase activity controls phagosomal proteolysis in macrophages through modulation of the luminal redox environment of phagosomes. Proc Natl Acad Sci USA. (2010) 107:10496–501. doi: 10.1073/pnas.0914867107
14. Allan ER, Tailor P, Balce DR, Pirzadeh P, McKenna NT, Renaux B, et al. NADPH oxidase modifies patterns of MHC class II-restricted epitopic repertoires through redox control of antigen processing. J Immunol (Baltimore, Md.: 1950). (2014) 192:4989–5001. doi: 10.4049/jimmunol.1302896
15. Liu C, Whitener RL, Lin A, Xu Y, Chen J, Savinov A, et al. Neutrophil cytosolic factor 1 in dendritic cells promotes autoreactive CD8(+) T cell activation via cross-presentation in type 1 diabetes. Front Immunol. (2019) 10:952. doi: 10.3389/fimmu.2019.00952

FUNDING

This study was supported by the National Natural Science Foundation of China (Nos. 81573802, 81503426, and 81874383) and the program of Tongji-Rongcheng Center for Biomedicine (HUST).

ACKNOWLEDGMENTS

Figures were created using BioRender.com.
30. Tan HY, Wang N, Li S, Hong M, Wang X, Feng Y. The reactive oxygen species in macrophage polarization: reflecting its dual role in progression and treatment of human diseases. Oxid Med Cell Longev. (2016) 2016:2795090. doi: 10.1155/2016/2795090

31. Wang P, Geng J, Gao J, Zhao H, Li J, Shi Y, et al. Macrophage achieves self-protection against oxidative stress-induced ageing through the Mfrn2 axis. Nat Commun. (2019) 10:755. doi: 10.1038/s41467-019-06880-6

32. Fernandez-Boyanapalli RF, Frasch SC, McPhillis K, Vandyver RW, Harry BL, Riches DW, et al. Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4. Blood. (2009) 113:2047–55. doi: 10.1182/blood-2008-05-160564

33. Sanmun D, Witasp E, Jitkaew S, Tyurina YY, Kagan VE, Ahlin A, et al. Involvement of a functional NADPH oxidase in neutrophils and macrophages during programmed cell clearance: implications for chronic granulomatous disease. Am J Physiol Cell Physiol. (2009) 297:C621–31. doi: 10.1152/ajpcell.00651.2008

34. Medina CB, Mehrotra P, Arandjelovic S, Perry JSA, Guo Y, Morioka S, et al. Metabolites released from apoptotic cells act as tissue messengers. Metabolites. (2020) S80:130–5. doi: 10.3390/s80134184

35. Luo B, Gan W, Liu Z, Shen Z, Wang J, Shi R, et al. Erythropoietin signaling in macrophages promotes dying cell clearance and immune tolerance. Immunity. (2016) 44:287–302. doi: 10.1016/j.immuni.2016.01.002

36. Luo B, Wang J, Liu Z, Shen Z, Shi R, Liu YQ, et al. Phagocyte respiratory burst activates macrophage erythropoietin signaling to promote acute inflammation resolution. Nat Commun. (2016) 7:12177. doi: 10.1038/ncomms12177

37. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Metabolites released from apoptotic cells act as tissue messengers. J Biol Chem. (2002) 277:49965–75. doi: 10.1074/jbc.M204513200

38. Tyurin VA, Balasubramanian K, Winnica D, Tyurina YY, Vikulina AS, et al. NADPH oxidase activation regulates apoptotic neutrophil clearance by murine macrophages. Blood. (2018) 131:2367–78. doi: 10.1182/blood-2017-09-809004

39. Zhao J, Ma J, Deng Y, Kelly JA, Kim K, Bang SY, et al. A missense variant in NCF1 is associated with susceptibility to multiple autoimmune diseases. Nat Genet. (2017) 49:433–7. doi: 10.1038/ng.3782

40. Campbell AM, Kashgarian M, Shlomchik MJ. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci Transl Med. (2012) 4:157ra141. doi: 10.1126/scitranslmed.3004801

41. Kienhöfer D, Hahn J, Stoof J, Csepregi JZ, Reinwald C, Urbanoviciute V, et al. Experimental lupus is aggravated in mouse strains with impaired induction of neutrophil extracellular traps. JCI Insight. (2017) 2:92920. doi: 10.1172/jci.insight.92920

42. Hahn J, Euler M, Kilgus E, Kienhöfer D, Stoof J, Knofl J, et al. NOX2 mediates quiescent handling of dead cell remnants in phagocytes. Redox Biol. (2019) 26:101279. doi: 10.1016/j.redox.2019.101279

43. Yang Y, Bazhin AV, Werner J, Karakhanova S. Reactive oxygen species in the immune system. Int Rev Immunol. (2013) 32:249–70. doi: 10.3109/08830185.2012.755176

44. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Ann Rev Immunol. (2013) 31:259–83. doi: 10.1146/annurev-immunol-032012-132150

45. Waickman AT, Powell JD. mTORC1, metabolism, and the regulation of T-cell differentiation and function. ImmunoL Rev. (2012) 249:43–58. doi: 10.1111/j.1600-065X.2012.01152.x

46. Sena LA, S L, Jairaman A, Prakriya M, Esponda T, Hildeman DA, et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity. (2013) 38:225–36. doi: 10.1016/j.immuni.2012.10.020

47. Previte DM, O’Connor EC, Novak EA, Martins CP, Mollen KP, Pignalli JD. Reactive oxygen species are required for driving efficient and sustained aerobic glycolysis during CD4+ T cell activation. PLoS ONE. (2017) 12:e0175549. doi: 10.1371/journal.pone.0175549

48. Moro-Garcia MA, Mayo JC, Sainz RM, Alonso-Arias R. Influence of inflammation in the process of T lymphocyte differentiation: proliferative, metabolic, oxidative changes. Front Immunol. (2018) 9:339. doi: 10.3389/fimmu.2018.00339

49. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (Baltimore, Md.: 1950). (1986) 136:2348–54.

50. Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol. (2001) 15:677–91. doi: 10.1053/berh.2001.0187

51. Wislowska M, Kuczewska-Stanecka K. Current views of etiopathogenesis in systemic lupus erythematosus. Polski tygodnik lekarski (Warsaw, Poland: 1960). (1986) 41:506–10.

52. Novack M, Miocce P, Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimm Rev. (2014) 13:668–77. doi: 10.1016/j.autrev.2013.12.004

53. Sakaguchi S, Vignali DA, Rudensky AY, Nicc RE, Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol. (2013) 13:461–7. doi: 10.1038/nri3464

54. Jackson SH, Devadas S, Kwon J, Pinto LA, Williams MS. T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat Immunol. (2004) 5:818–27. doi: 10.1038/ni1096

55. Shatyński KE, Chen H, Kwon J, Williams MS. Decreased STAT5 phosphorylation and GATA-3 expression in NOX2-deficient T cells role in T helper development. Eur J Immunol (1996) 26:1220–21. doi: 10.1002/eji.1051742659

56. Kraaj MD, Savage ND, van der Kooij SW, Koekkoek K, Wang J, van den Berg JM, et al. Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proc Natl Acad Sci USA. (2010) 107:17866–91. doi: 10.1073/pnas.1002161107

57. Efimova O, Szankasi P, Kelley TW. Ncf1 (p47phox) is essential for direct regulatory T cell mediated suppression of CD4+ effector T cells. PLoS ONE. (2011) 6:e16013. doi: 10.1371/journal.pone.0061013

58. Padgett LE, Tse HM. NADPH oxidase-derived superoxide provides a third signal for CD4+ T cell effector responses. J Immunol (Baltimore, Md.: 1950). (2016) 197:1733–42. doi: 10.4049/jimmunol.1502581
67. Tse HM, Thayer TC, Steele C, Cuda CM, Morel L, Piganelli JD, et al. NADPH oxidase deficiency regulates Th lineage commitment and modulates autoimmunity. *J Immunol (Baltimore, Md.: 1950).* (2010) 185:5247–58. doi: 10.4049/jimmunol.1001472

68. Gelderman KA, Hultqvist M, Pizzolla A, Zhao M, Nandakumar KS, Mattsson R, et al. Macrophages suppress T cell responses and arthritis development in mice by producing reactive oxygen species. *J Clin Invest.* (2007) 117:3020–8. doi: 10.1172/JCI31935

69. Yang Z, Shen Y, Oishi H, Matteson EL, Goronzy JJ, et al. Restoring oxidant signaling suppresses proinflammatory T cell effector functions in rheumatoid arthritis. *Sci Transl Med.* (2016) 8:331ra38. doi: 10.1126/scitranslmed.aad7151

70. Thayer TC, Delano M, Liu C, Chen J, Padgett LE, Tse HM, et al. Superoxide production by macrophages and T cells is critical for the induction of autoreactivity and type 1 diabetes. *Diabetes.* (2011) 60:2144–51. doi: 10.2337/db10-1222

71. Padgett LE, Burg AR, Lei W, Tse HM. Loss of NADPH oxidase-derived superoxide skews macrophage phenotypes to delay type 1 diabetes. *Diabetes.* (2015) 64:937–46. doi: 10.2337/db14-0929

72. Seleme MC, Lei W, Burg AR, Goh KY, Metz A, Steele C, et al. Dysregulated TLR3-dependent signaling and innate immune activation in superoxide-deficient macrophages from nonobese diabetic mice. *Free Radic Biol Med.* (2012) 52:3047–56. doi: 10.1016/j.freeradbiomed.2012.01.027

73. Padgett LE, Anderson B, Liu C, Ganini D, Mason RP, Piganelli JD, et al. Loss of NOX-derived superoxide exacerbates diabetic CD4+ T cell effector responses in type 1 diabetes. *Diabetes.* (2015) 64:1471–83. doi: 10.2337/db15-0546

74. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. *Proc Natl Acad Sci USA.* (1998) 95:3071–6. doi: 10.1073/pnas.95.6.3071

75. Camins MM, Sauer SW, Klemke CD, Süss D, Okun JG, Krammer PH, et al. Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated TGF-β-mediated TGF-β cytokine activation. *Immunity.* (2019) 51:671–81.e5. doi: 10.1016/j.immuni.2019.08.001

76. Yang Z, Fujii H, Mohan SV, Goronzy JJ, Weyand CM. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. *J Exp Med.* (2015) 210:2119–34. doi: 10.1084/jem.20130252

77. Zhao C, Gu Y, Zeng X, Wang J. NLRP3 inflammasome regulates Th17 differentiation in rheumatoid arthritis. *Clin Immunol (Orlando, Fla.).* (2018) 197:154–60. doi: 10.1016/j.clim.2018.09.007

78. Abimann T, Peroumal D, Parida JR, Barik PK, Padhan P, Devadas S. Oxidative stress modulates the cytokine response of differentiated Th1 and Th2 cells. *Free Radic Biol Med.* (2016) 99:352–63. doi: 10.1016/j.freeradbiomed.2016.08.026

79. van de Geer A, Cuadrado E, Slot MC, van Bruggen R, Amsen D, Kuijpers TW. Regulatory T cell features in chronic granulomatous disease. *Nat Immunol.* (2015) 64:4171–83. doi: 10.1038/s41590-019-0577-9

80. Dan L, Liu L, Yao D, Liu L, Kim E, Trinath J, Lu J, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. *Nature.* (2019) 576:143–8. doi: 10.1038/s41586-019-1785-z

81. Gelderman KA, Hultqvist M, Holmberg J, Olofsson P, Holmdahl R. T cell surface redox levels determine T cell reactivity and arthritis susceptibility. *Proc Natl Acad Sci USA.* (2006) 103:12831–6. doi: 10.1073/pnas.0604571103

82. Yang Z, Fuji H, Mohan SV, Goronzy JJ, Weyand CM. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. *J Exp Med.* (2015) 210:2119–34. doi: 10.1084/jem.20130252

83. Xu Y, Lao Y, Teng XL, Li S, Zhou Y, Wang F, et al. SENP3 maintains the stability and function of regulatory T cells via BACH2 deSUMOylation. *Nat Commun.* (2018) 9:3157. doi: 10.1038/s41467-018-05676-6

84. Liu D, Liu L, Ji X, Gao X, Chen X, Liu Y, et al. The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates Th17 differentiation. *Immunity.* (2015) 16:1263–73. doi: 10.1016/j.immuni.2015.06.016

85. Peri A. Oxidative stress in the pathology and treatment of systemic lupus erythematosus. *Nat Rev Rheumatol.* (2013) 9:674–86. doi: 10.1038/nrrheum.2013.147

86. Efimov I, Basran J, Thackray SJ, Handsa S, Mowat CG, Raven EL. Structure and reaction mechanism in the heme dioxygenases. *Biochemistry.* (2011) 50:2717–24. doi: 10.1016/biochem.2010.08.091

87. Thomas SR, Terentis AC, Cai H, Takikawa O, Levinia A, Lay PA, et al. Post-transcriptional regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. *J Biol Chem.* (2007) 282:23778–87. doi: 10.1074/jbc.M700692000

88. Mándy Y, Vecsei L. The kynurenine system and immunoregulation. *J Neurotransm (Vienna, Austria).* (1996). (2012) 119:197–209. doi: 10.1007/s00702-011-0681-y

89. Maghlz GI, Thomas SR, Hunt NH, Stocker R. Cytokine b3, not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells. *J Biol Chem.* (2008) 283:12014–25. doi: 10.1074/jbc.M702662000

90. Romaní L, Fallarino F, De Luca A, Montagnoli C, D’Angelo C, Zelante T, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. *Nature.* (2008) 451:211–5. doi: 10.1038/nature06471

91. He Y, Dang Y, Wei LE, Brown OR. Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. *Free Radic Biol Med.* (2000) 28:615–24. doi: 10.1016/s0891-5849(99)00272-5

92. Kim HR, Lee A, Choi EJ, Hong MP, Kie JH, Lim W, et al. Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function. *PLoS ONE.* (2014) 9:e91146. doi: 10.1371/journal.pone.0091146

93. Kim HR, Kim JH, Choi EJ, Lee YK, Kie JH, Jang MH, et al. Hyperoxegenation attenuates a murine model of dermatisic dermatitis through raising skin level of ROS. *PLoS ONE.* (2014) 9:e109257. doi: 10.1371/journal.pone.0109257

94. Popov A, Abdullah Z, Wickenhauser C, Saric T, Driesen J, Hanisch FG, et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells form supportive
granulomas following Listeria monocytogenes infection. J Clin Investig. (2006) 116:3160–70. doi: 10.1172/JCI28996
106. De Ravin SS, Zarembka KA, Long-Priel D, Chan KC, Fox SD, Gallin JI, et al. Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease. Blood. (2010) 116:1755–60. doi: 10.1182/blood-2009-07-233734
107. Jürgens B, Fuchs D, Reichenbach J, Heitger A. Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease. Clin Immunol (Orlando, Fla.). (2010) 137:1–4. doi: 10.1016/j.clim.2010.05.007
108. Maghzal GJ, Winter S, Wurzer B, Chong BH, Holmdahl R, Stocker R. Tryptophan catabolism is unaffected in chronic granulomatous disease. Nature. (2014) 514:616–7. doi: 10.1038/nature13844
109. Vottero E, Mitchell DA, Page MJ, MacGillivray RT, Sadowski IJ, Roberge AM, et al. The neglected significance of “antioxidative stress”. Am J Pathol. (2016) 188:1571–9. doi: 10.1016/j.ajpath.2016.05.014
110. Hill M, Tanguy-Royer S, Royer P, Chauveau C, Asghar K, Tessson L, et al. Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis. J Immunol (Baltimore, Md.: 1950). (2012) 188:3869–77. doi: 10.4049/jimmunol.1201236
111. Maghzal GJ, Winter S, Wurzer B, Chong BH, Holmdahl R, Stocker R. Deficiency of reactive oxygen species protects against autoimmune priming of T cells. J Exp Med. (2013) 210:2437–51. doi: 10.1084/jem.20130048
112. Rashida Gnanaprakasam JN, Wu R, Wang R. Metabolic reprogramming in modulating T cell reactive oxygen species generation and antioxidant capacity. Front Immunol. (2018) 9:1075. doi: 10.3389/fimmu.2018.01075
113. Metzler B, Gflerrer P, Guinet E. Restricting glutamine or glutamine-dependent purine and pyrimidine synthesis promotes human T cells with high FOXP3 expression and regulatory properties. J Immunol (Baltimore, Md.: 1950). (2007) 179:141–51. doi: 10.4049/jimmunol.179.3.141
114. Battersby AC, Braggins H, Pearce MS, Cale CM, Burns SO, Hackett S, et al. Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom. J Allergy Clin Immunol. (2017) 140:628–30. e6. doi: 10.1016/j.jaci.2017.02.029
115. Hultqvist M, Bäcklund J, Bauer K, Gelderman KA, Holmdahl R. Lack of reactive oxygen species breaks T cell tolerance to collagen type II and allows development of arthritis in mice. J Exp Med. (2007) 204:1431–49. doi: 10.1084/jem.20062419
116. Telang S, Clem BF, Klarer AC, Clem AL, Trent JO, Bucala R, et al. Small molecule inhibition of 6-phosphofructo-2-kinase suppresses T cell activation. J Transl Med. (2012) 10:95. doi: 10.1186/1479-5868-10-95
117. Rashida G nanaprakasam JN, Wu R, Wang R. Metabolic reprogramming in modulating T cell reactive oxygen species generation and antioxidant capacity. Front Immunol. (2018) 9:1075. doi: 10.3389/fimmu.2018.01075
118. Metzler B, Gflerrer P, Guinet E. Restricting glutamine or glutamine-dependent purine and pyrimidine synthesis promotes human T cells with high FOXP3 expression and regulatory properties. J Immunol (Baltimore, Md.: 1950). (2007) 179:141–51. doi: 10.4049/jimmunol.179.3.141
circuits in control of T cell migration and effector functions. *PLoS Biol.* (2015) 13:e1002202, doi: 10.1371/journal.pbio.1002202

145. Pucino V, Bombardieri M, Pittalizzi C, Mauro C. Lactate at the crossroads of metabolism, inflammation, and autoimmunity. *Eur J Immunol.* (2017) 47:14–21, doi: 10.1002/eji.201646477

146. Ivashkiv LB, The hypoxia-lactate axis tempers inflammation. *Nat Rev Immunol.* (2020) 20:85–6, doi: 10.1038/s41577-019-0259-8

147. Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic regulation of gene expression by histone lactylation. *Nature.* (2019) 574:575–80, doi: 10.1038/s41586-019-1678-1

148. Devaraj S, Jialal I. Oxidized low-density lipoprotein and atherosclerosis. *Int J Clin Lab Res.* (1996) 26:178–84, doi: 10.1007/BF02592979

149. Batooei M, Tahamoli-Roudsari A, Basiri Z, Yaserifar F, Shahdoust M, Eshraghi A, et al. Evaluating the effect of oral N-acetylcysteine as an adjuvant treatment on clinical outcomes of patients with rheumatoid arthritis: a randomized, double blind clinical trial. *Rev Recent Clin Trials.* (2018) 13:132–8, doi: 10.2174/1574887113666180307151937

150. León Fernández OS, Viebahn-Haensler R, Cabreja GL, Espinosa IS, Matos YH, Roche LD, et al. Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis. *Eur J Pharmacol.* (2016) 789:313–8, doi: 10.1016/j.ejphar.2016.07.031

151. Abdollahzad H, Aghdashi MA, Asghari Jafarabadi M, Alipour B. Effects of coenzyme Q10 supplementation on inflammatory cytokines (TNF-α, IL-6) and oxidative stress in rheumatoid arthritis patients: a randomized controlled trial. *Arch Med. Res.* (2015) 46:527–33, doi: 10.1016/j.arcmed.2015.08.006

152. Nikki E. Oxidant-specific biomarkers of oxidative stress. Association with atherosclerosis and implication for antioxidant effects. *Free Radic Biol Med.* (2018) 120:425–40, doi: 10.1016/j.freeradbiomed.2018.04.001

153. Sun T, Jiang D, Rosenkranz ZT, Ehlerding EB, Ni D, Qi C, et al. A melanin-based natural antioxidant defense nanosystem for theranostic application in acute kidney injury. *Adv Funct Mater.* (2019) 29:1904833, doi: 10.1002/adfm.201904833

154. Bao Q, Hu P, Xu Y, Cheng T, Wei C, Pan L, et al. Simultaneous blood-brain barrier crossing and protection for stroke treatment based on edaravone-loaded ceria nanoparticles. *ACS Nano.* (2018) 12:6794–805, doi: 10.1021/acsnano.8b01994

155. Aviello G, Knaus UG. NADPH oxidases and ROS signaling in the gastrointestinal tract. *Mucosal Immunol.* (2018) 11:1011–23, doi: 10.1038/s41385-018-0021-8

156. Nóbrega-Pereira S, Fernandez-Marcos PJ, Briacho T, Gomez-Cabrera MC, Salvador-Pascual A, Flores JM, et al. G6PD protects from oxidative damage and improves healthspan in mice. *Nat Commun.* (2016) 7:10894, doi: 10.1038/ncomms10894

157. Batinic-Haberle I, Tome ME. Thiol regulation by Mn porphyrins, commonly known as SOD mimics. *Redox Biol.* (2019) 25:101139, doi: 10.1016/j.redox.2019.101139

158. Carter CS, Huang SC, Searby CC, Cassady B, Miller MJ, Grzesik WJ, et al. Exposure to static magnetic and electric fields treats type 2 diabetes. *Cell Metab.* (2020) 32:1076, doi: 10.1016/j.cmet.2020.11.001

159. Ristow M, Schmeisser K. Mitohormesis: promoting health and lifespan by increased levels of reactive oxygen species (ROS). *Dose Response.* (2014) 12:288–341, doi: 10.2203/dose-response.13-035.

160. Merry TL, Ristow M. Do antioxidant supplements interfere with skeletal muscle adaptation to exercise training? *J Physiol.* (2016) 594:5135–47, doi: 10.1113/JP270654

161. Ristow M, Zarse K. How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). *Exp Gerontol.* (2010) 45:410–8, doi: 10.1016/j.exger.2010.03.014

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Lin, Shen, Song, Huang and Tu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.